An analysis of three independent cohorts, which included a 179-patient Stanford University cohort (GSE3500), a 45-patient Mount Sinai Liver Cancer Program cohort (GSE6764), and a 445-patient National Cancer Institute cohort (GSE14520), proved that PTPN13 expression was downregulated in HCC tissue (Fig. S4B–D). Here, PTPN13 is linked to liver cancer.